Regenxbio, UPenn file patent suit against Sarepta related to new Duchenne gene therapy

Re­genxbio, a Rockville, MD-based biotech, and the Uni­ver­si­ty of Penn­syl­va­nia sued Sarep­ta Ther­a­peu­tics for the sec­ond time, this time al­leg­ing patent in­fringe­ment for the com­pa­ny’s new­ly ap­proved gene ther­a­py for Duchenne mus­cu­lar dy­s­tro­phy.

The suit, filed last week in US Dis­trict Court in the dis­trict of Delaware, al­leges that Sarep­ta and Catal­ent, which man­u­fac­tures Sarep­ta’s gene ther­a­pies, vi­o­lat­ed a patent for Ele­v­idys, the brand name of Sarep­ta’s Duchenne treat­ment that re­ceived FDA ap­proval last week.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN